Study Details

Back
Study ID BR.21
Study Title A Randomized Placebo-Controlled Study of OSI-774 (Tarceva™) in Patients With Incurable Stage IIIB/IV Non-Small Cell Lung Cancer Who Have Failed Standard Therapy For Advanced or Metastatic Disease
Clinicaltrials.gov Identifier NCT00036647
Compound Name OSI-774 / erlotinib
Medical Indication or Disease Non-small cell lung cancer
Study Sponsor OSI Pharmaceuticals, Inc.
Collaborator NCIC Clinical Trials Group
Study Start Date 01-Nov-2001
Study Completion Date 30-Jan-2004
Clinical Study Result
Select the language
English
Plain Language Summary
Select the language
English

QUICK SEARCH

USEFUL LINKS